Louis Philipson to Cost-Benefit Analysis
This is a "connection" page, showing publications Louis Philipson has written about Cost-Benefit Analysis.
Connection Strength
0.181
-
Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014; 37(1):202-9.
Score: 0.093
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
Score: 0.044
-
A review of the mental health issues of diabetes conference. Diabetes Care. 2015 Feb; 38(2):333-8.
Score: 0.026
-
The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Diabetes Care. 2011 Mar; 34(3):622-7.
Score: 0.019